½ÃÀ庸°í¼­
»óǰÄÚµå
1578764

º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ(2024-2033³â)

Vietnam Human Vaccines Import Research Report 2024-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: China Research and Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 80 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àΰ£¿ë ¹é½ÅÀº ¼ö³â°£ ¿¹¹æ È¿°ú¸¦ ¹ßÈÖÇÏ¿© Àΰ£ÀÇ °Ç°­¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Çö´ë »ýȰ¿¡¼­ ¿¹¹æ Á¢Á¾Àº ƯÁ¤ Áúº´, ƯÈ÷ Àü¿°º´°ú °¨¿°À¸·ÎºÎÅÍ ¿¹¹æÇÏ´Â °¡Àå È¿°úÀûÀÎ ¹æ¹ýÀ¸·Î ³Î¸® »ç¶÷µé¿¡°Ô ¹Þ¾Æ µé¿©Áö°í ÀÖ½À´Ï´Ù.

ÀÎÆ÷±×·¡ÇȽº

º£Æ®³² ÃÑ Àα¸´Â 2023³â ¸» 1¾ï ¸íÀ» µ¹ÆÄÇÏ¸ç ¸Å³â 100¸¸ ¸í ÀÌ»óÀÇ ¼øÀα¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °æÁ¦°¡ ¹ßÀüÇϰí ÀÚº»¼ÒµæÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º£Æ®³²ÀÇ ÀǾàǰ »ê¾÷Àº °­·ÂÇÏ°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º£Æ®³² Á¤ºÎ´Â Áö¿ø Á¤Ã¥À» Áö¼ÓÀûÀ¸·Î ³»¼¼¿ì°í ÀÇ·á ÁöÃâÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. CRI¿¡ µû¸£¸é º£Æ®³²ÀÇ ÀÚÀ¯ ¹«¿ª ÇùÁ¤Àº Á¦¾à »ê¾÷¿¡¼­ ¿Ü±¹ ±â¾÷ ½ÃÀå ÁøÀÔ À庮À» ¾ø¾Ö°í À¯·´°ú ÀϺΠÁö¿ªÀÇ ÀǾàǰ ¼öÀÔ °ü¼¼´Â ¸Å¿ì ³·°Å³ª Á¸ÀçÇÏÁö ¾ÊÀ» ¼öµµ ÀÖ½À´Ï´Ù. º£Æ®³²ÀÇ Á¦¾à »ê¾÷Àº ¼öÀÔ ÀǾàǰ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

¹é½ÅÀº ƯÁ¤ Áúº´À» ¿¹¹æÇϰí Áúº´ÀÇ È®»êÀ» ¾ïÁ¦ÇÏ¸ç °øÁß º¸°ÇÀ» Çâ»ó½Ãŵ´Ï´Ù. CRI´Â º£Æ®³²¿¡¼­ Àΰ£¿ë ¹é½Å ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ´Ù°í ºÐ¼®Çß½À´Ï´Ù. ±×·¯³ª ±¹³» »ý»ê ´É·ÂÀÌ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ½ÃÀåÀº ÁÖ·Î ¼öÀÔ Á¦Ç°¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. ÃÖ±Ù º£Æ®³²Àº COVID-19 ¹é½Å, ÀÎÇ÷翣ÀÚ ¹é½Å, HPV ¹é½Å, 4°¡ ¹× 6°¡ ¼Ò¾Æ ¹é½Å µî ¼ö¸¹Àº ¹é½ÅÀ» ¼öÀÔÇϰí ÀÖ½À´Ï´Ù. º£Æ®³²ÀÇ ¹é½Å ¼ö¿ä´Â ³ô°í, ƯÈ÷ COVID-19 ÀÌÈÄ¿¡´Â Á¤ºÎ³ª ±¹¹Î ¸ðµÎ °Ç°­À» Áß½ÃÇÏ°Ô µÇ¾î, ¼öÀԵǴ Àΰ£¿ë ¹é½ÅÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹é½Å »ê¾÷¿¡´Â ¿ø·á °ø±Þ(Ç׿ø, º¸Á¶Á¦ µî), Á¦Á¶(¿¬±¸, Á¦Á¶, ǰÁú °ü¸® µî)¿Í °°Àº ¾÷½ºÆ®¸² ºÎ¹®°ú À¯Åë ¹× ¿¹¹æÁ¢Á¾ ¼­ºñ½º µî ´Ù¿î½ºÆ®¸² ºÎ¹®ÀÌ ÀÖ½À´Ï´Ù. ¹é½Å Á¦Á¶¿¡´Â ¾ö°ÝÇÑ À§»ý Á¶°Ç, °í±Þ Á¦Á¶ ¼³ºñ ¹× ±â¼ú, ³ôÀº ¼öÁØÀÇ Ç°Áú °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. ¼¼°èÀÇ ÁÖ¿ä ¹é½Å Á¦Á¶ ¹× ¼öÃâ ±â¾÷Àº Pfizer, Modernna, AstraZeneca µî °­·ÂÇÑ ¿¬±¸°³¹ß´É·ÂÀ» Áö´Ñ ¼±µµÀûÀÎ ¹ÙÀÌ¿À ÀǾàǰ ±â¾÷À̸ç, ÇöÀç º£Æ®³² ±¹³» ±â¾÷Àº ÇÑÁ¤µÈ À¯ÇüÀÇ ¹é½Å¸¸ Á¦Á¶ÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19¿¡¼­ º£Æ®³²Àº ±ä±Þ ¼ö¿ä¿¡ ºÎÀÀÇϱâ À§ÇØ »ó´ç¼öÀÇ ¹é½ÅÀ» ¼öÀÔÇß½À´Ï´Ù. CRI¿¡ µû¸£¸é º£Æ®³²¿¡¼­´Â Àΰ£¿ë ¹é½Å Á¦Á¶ÀÇ ÀÎÇÁ¶ó¿Í ±â¼úÀÌ ¹ß´ÞµÇÁö ¾Ê¾Ò±â ¶§¹®¿¡ °ø±ÞÀº ±¹Á¦ ½ÃÀå¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º£Æ®³² Á¤ºÎ´Â °øÁß º¸°Ç¿¡ ¸Å¿ì ÈûÀ» ½ñ°í ÀÖÀ¸¸ç ÀϹÝÀûÀÎ °¨¿°À» ´Ù·ç´Â ±¹°¡ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥(NIP)À» ÅëÇØ ¹é½Å Á¢Á¾·ü Çâ»óÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. º£Æ®³²Àº ¹é½ÅÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» º¸ÀåÇϱâ À§ÇØ ´Ù¾çÇÑ ±¹Á¦Àû ¹é½Å °ø±Þ¾÷ü¿Í Çù·Â ÇùÁ¤À» ¸Î°í ÀÖ½À´Ï´Ù.

CRI µ¥ÀÌÅÍ¿¡ µû¸£¸é º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ ÃѾ×Àº 2023³â 4¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¶ÇÇÑ 2024³â 1¿ùºÎÅÍ 5¿ù±îÁö º£Æ®³² ¹é½Å ¼öÀÔ ÃѾ×Àº 2¾ï 5,000¸¸ ´Þ·¯¸¦ ³Ñ¾î Àü³â ´ëºñ 30% ÀÌ»óÀÇ ¼ºÀå¼¼¸¦ º¸¿´½À´Ï´Ù. ÀÌ Ãß¼¼´Â ¾ÕÀ¸·Î ¼ö³â°£ ¾ÈÁ¤ÀûÀÎ ¼ºÀå·ü·Î Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü¹ÝÀûÀ¸·Î º£Æ®³² Àα¸ Áõ°¡¿Í °æÁ¦ ¼öÁØ »ó½Â ¿Ü¿¡µµ °Ç°­¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶¿¡ µû¶ó º£Æ®³² Àΰ£¿ë ¹é½Å ½ÃÀå ±Ô¸ð°¡ È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. CRI ºÐ¼®¿¡ µû¸£¸é ±¹»ê Àΰ£¿ë ¹é½ÅÀÇ »ý»ê ´É·Â°ú ±â¼ú ¼öÁØÀÌ ºñ±³Àû ³·±â ¶§¹®¿¡ º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔÀº ÇâÈÄ ¼ö³â°£ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ µ¿ÇâÀ» Á¶»çÇÏ¿© ±¹°¡ °³¿ä, ¼öÀÔ¾×, ¼öÀÔ·® ¹× ¼öÀÔ °¡°Ý µîÀÇ ÃßÀÌ ¹× ¿¹Ãø, ¼öÀÔ¿ø »óÀ§ ±¹°¡º° »ó¼¼ ºÐ¼®, ÁÖ¿ä ¹ÙÀÌ¾î ¹× °ø±ÞÀÚ ºÐ¼®, ¸ñÁ¦ °¡±¸ ¼öÃâ¿¡ ´ëÇÑ ÁÖ¿ä ¿µÇâ¿äÀÎ ºÐ¼® µîÀ» ¿ä¾àÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå º£Æ®³² °³¿ä

  • Áö¿ª
  • °æÁ¦ »óȲ
  • Àα¸Åë°è
  • ±¹³» ½ÃÀå
  • Àΰ£¿ë ¹é½Å ¼öÀÔ ½ÃÀå¿¡ Âü°¡ÇÏ´Â ¿Ü±¹ ±â¾÷¿¡ ´ëÇÑ ±Ç°í

Á¦2Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔÀÇ ºÐ¼®(2021-2024³â)

  • ¼öÀÔ±Ô¸ð
    • ¼öÀÔ¾× ¹× ¼öÀÔ·®
    • ¼öÀÔ°¡°Ý
    • ¼Òºñ·®
    • ¼öÀÔ ÀÇÁ¸µµ
  • Àΰ£¿ë ¹é½ÅÀÇ ÁÖ¿ä ¼öÀÔ¿ø

Á¦3Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½ÅÀÇ ÁÖ¿ä ¼öÀÔ¿ø ºÐ¼®(2021-2024³â)

  • ¹Ì±¹
    • ¼öÀÔ·® ¹× ¼öÀÔ¾×ÀÇ ºÐ¼®
    • Æò±Õ ¼öÀÔ °¡°Ý ºÐ¼®
  • ÇÁ¶û½º
    • ¼öÀÔ·® ¹× ¼öÀÔ¾×ÀÇ ºÐ¼®
    • Æò±Õ ¼öÀÔ °¡°Ý ºÐ¼®
  • º§±â¿¡
    • ¼öÀÔ·® ¹× ¼öÀÔ¾×ÀÇ ºÐ¼®
    • Æò±Õ ¼öÀÔ °¡°Ý ºÐ¼®
  • ű¹
  • ³×´ú¶õµå
  • Àεµ

Á¦4Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ ½ÃÀåÀÇ ÁÖ¿ä °ø±ÞÀÚ ºÐ¼®(2021-2024³â)

  • GLAXOSMITHKLINE BIOLOGICALS SA
  • MERCK SHARP & DOHME(ASIA) LTD
  • SANOFI PASTEUR
  • ±âŸ
    • ±â¾÷ °³¿ä
    • Àΰ£¿ë ¹é½Å ¼öÃ⠺м®

Á¦5Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ ½ÃÀåÀÇ ÁÖ¿ä ¼öÀÔ¾÷ü ºÐ¼®(2021-2024³â)

  • GSK PHARMA VIETNAM COMPANY
  • MSD HH VIETNAM LTD
  • SANOFI-AVENTIS VIETNAM COMPANY
  • ±âŸ
    • ±â¾÷ °³¿ä
    • Àΰ£¿ë ¹é½Å ¼öÀÔÀÇ ºÐ¼®

Á¦6Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔÀÇ ¿ùº° ºÐ¼®(2021-2024³â)

  • ¿ùº° ¼öÀÔ¾× ¹× ¼öÀÔ·®ÀÇ ºÐ¼®
  • ¿ùÆò±Õ ¼öÀÔ°¡°Ý ¿¹Ãø

Á¦7Àå º£Æ®³²ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ¿¡ ¿µÇâÀ» ÁÖ´Â ÁÖ¿ä ¿äÀÎ

  • Á¤Ã¥
    • ÇöÀç ¼öÀÔÁ¤Ã¥
    • ¼öÀÔ Á¤Ã¥ÀÇ µ¿Çâ ¿¹Ãø
  • °æÁ¦
    • ½ÃÀå °¡°Ý
    • Àΰ£¿ë ¹é½Å »ý»ê ´É·ÂÀÇ ¼ºÀå µ¿Çâ
  • ±â¼ú

Á¦8Àå º£Æ®³²¿¡¼­ÀÇ Àΰ£¿ë ¹é½Å ¼öÀÔ ¿¹Ãø

¸éÃ¥»çÇ×

¼­ºñ½º º¸Áõ

AJY 24.11.04

Human vaccines offer longstanding protection, playing an indispensable role in human health. In modern life, vaccination has become the most effective way to prevent from specific diseases, especially pestilences and infection, widely accepted by people.

INFOGRAPHICS

By the end of 2023, Vietnam's total population has surpassed 100 million, with a net population growth of more than 1 million annually. As the economy progressing and capital income increasing, the pharmaceutical industry in Vietnam is growing vigorously. Also, the Vietnam government continues to issue support policies and expand healthcare spending. For example, the national strategy for pharmaceutical industry development through 2030, with a vision to 2045 approved in 2023 set out clear development targets for specific industry including vaccines. According to CRI, Vietnam's free trade agreements have removed market access barriers for foreign companies in its pharmaceutical industry, and import tariffs on medicines from Europe and some regions are very low or even non-existent. Vietnam's pharmaceutical industry is highly dependent on imported pharmaceutical products.

Vaccines can prevent certain diseases, reduce the spread of illness, and improve public health. CRI has analyzed that the demand for human vaccines in Vietnam is steadily increasing. However, due to limited domestic production capacity, Vietnam's human vaccine market mainly relies on imported products. In recent years, Vietnam has imported a large number of vaccines, including COVID-19 vaccines, influenza vaccines, HPV vaccines, and quadrivalent and hexavalent pediatric vaccines. The demand for vaccines in Vietnam is high, especially in the post-COVID-19 era, as both the government and the public place greater emphasis on health, leading to an increase in the number of imported human vaccines.

The vaccine industry involves upstream sectors such as raw material supply (e.g., antigens, adjuvants), manufacturing (including research, production, and quality control), and downstream sectors like distribution and vaccination services. Vaccine production requires strict hygiene conditions, advanced production equipment and technology, and high standards of quality control. Leading global vaccine producers and exporters are typically large biopharmaceutical companies with strong R&D capabilities, such as Pfizer, Moderna, and AstraZeneca. Currently, Vietnamese domestic companies are only able to produce a limited variety of vaccines.

During the COVID-19 pandemic, Vietnam imported a significant number of vaccines to meet the urgent demand. According to CRI, because of the underdeveloped infrastructure and technology for human vaccine production in Vietnam, the country is heavily reliant on the international market for supply. Moreover, the Vietnamese government is highly committed to public health, promoting higher vaccination rates through the National Immunization Program (NIP), which covers a range of common infectious diseases. Vietnam has entered into cooperation agreements with various international vaccine suppliers to ensure a stable supply of vaccines.

Based on data from CRI, in 2023, Vietnam's total imports of human vaccines reached USD 470 million. From January to May 2024, Vietnam's total vaccine imports exceeded USD 250 million, representing a year-on-year growth of over 30%. This trend is expected to continue at a steady growth rate in the coming years.

CRI's analysis reveals that from 2021 to 2024, Vietnam's primary sources of human vaccine imports were the United States, France, and Belgium. Major companies exporting human vaccines to Vietnam include GlaxoSmithKline Biologicals S.A., Merck Sharp & Dohme (Asia) Ltd., and Sanofi Pasteur.

The main importers of human vaccines in Vietnam are pharmaceutical companies, distributors, and logistics providers, mostly foreign enterprises, such as GSK Pharma Vietnam Company, MSD HH Vietnam Ltd., and Sanofi-Aventis Vietnam Company.

Overall, with Vietnam's growing population and rising economic level, coupled with increased awareness of health, the size of Vietnam's human vaccine market is set to expand. CRI's analysis indicates that due to the relatively low production capacity and technological levels of domestic human vaccines, Vietnam's human vaccine imports are expected to continue growing in the coming years.

Topics covered:

The Import and Export of Human Vaccines in Vietnam (2021-2024)

Total Import Volume and Percentage Change of Human Vaccines in Vietnam (2021-2024)

Total Import Value and Percentage Change of Human Vaccines in Vietnam (2021-2024)

Total Import Volume and Percentage Change of Human Vaccines in Vietnam (2024)

Total Import Value and Percentage Change of Human Vaccines in Vietnam (2024)

Average Import Price of Human Vaccines in Vietnam (2021-2024)

Top 10 Sources of Human Vaccines Imports in Vietnam and Their Supply Volume

Top 10 Suppliers in the Import Market of Human Vaccines in Vietnam and Their Supply Volume

Top 10 Importers of Human Vaccines in Vietnam and Their Import Volume

How to Find Distributors and End Users of Human Vaccines in Vietnam

How Foreign Enterprises Enter the Human Vaccines Market of Vietnam

Forecast for the Import of Human Vaccines in Vietnam (2024-2033)

Table of Contents

1 Overview of Vietnam

  • 1.1 Geography of Vietnam
  • 1.2 Economic Condition of Vietnam
  • 1.3 Demographics of Vietnam
  • 1.4 Domestic Market of Vietnam
  • 1.5 Recommendations for Foreign Enterprises Entering the Vietnam Human Vaccines Imports Market

2 Analysis of Human Vaccines Imports in Vietnam (2021-2024)

  • 2.1 Import Scale of Human Vaccines in Vietnam
    • 2.1.1 Import Value and Volume of Human Vaccines in Vietnam
    • 2.1.2 Import Prices of Human Vaccines in Vietnam
    • 2.1.3 Apparent Consumption of Human Vaccines in Vietnam
    • 2.1.4 Import Dependency of Human Vaccines in Vietnam
  • 2.2 Major Sources of Human Vaccines Imports in Vietnam

3 ANALYSIS OF MAJOR SOURCES OF HUMAN VACCINES IMPORTS IN VIETNAM (2021-2024)

  • 3.1 United States
    • 3.1.1 Analysis of Vietnam's Human Vaccines Import Volume and Value from the United States
    • 3.1.2 Analysis of Average Import Price
  • 3.2 France
    • 3.2.1 Analysis of Vietnam's Human Vaccines Import Volume and Value from France
    • 3.2.2 Analysis of Average Import Price
  • 3.3 Belgium
    • 3.3.1 Analysis of Vietnam's Human Vaccines Import Volume and Value from Belgium
    • 3.3.2 Analysis of Average Import Price
  • 3.4 Thailand
  • 3.5 Netherlands
  • 3.6 India

4 Analysis of Major Suppliers in the Import Market of Human Vaccines in Vietnam (2021-2024)

  • 4.1 GLAXOSMITHKLINE BIOLOGICALS S A
    • 4.1.1 Company Introduction
    • 4.1.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.2 MERCK SHARP & DOHME (ASIA) LTD
    • 4.2.1 Company Introduction
    • 4.2.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.3 SANOFI PASTEUR
    • 4.3.1 Company Introduction
    • 4.3.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.4 Exporter 4
    • 4.4.1 Company Introduction
    • 4.4.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.5 Exporter 5
    • 4.5.1 Company Introduction
    • 4.5.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.6 Exporter 6
    • 4.6.1 Company Introduction
    • 4.6.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.7 Exporter 7
    • 4.7.1 Company Introduction
    • 4.7.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.8 Exporter 8
    • 4.8.1 Company Introduction
    • 4.8.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.9 Exporter 9
    • 4.9.1 Company Introduction
    • 4.9.2 Analysis of Human Vaccines Exports to Vietnam
  • 4.10 Exporter 10
    • 4.10.1 Company Introduction
    • 4.10.2 Analysis of Human Vaccines Exports to Vietnam

5 Analysis of Major Importers in the Import Market of Human Vaccines in Vietnam (2021-2024)

  • 5.1 GSK PHARMA VIETNAM COMPANY
    • 5.1.1 Company Introduction
    • 5.1.2 Analysis of Human Vaccines Imports
  • 5.2 MSD HH VIETNAM LTD
    • 5.2.1 Company Introduction
    • 5.2.2 Analysis of Human Vaccines Imports
  • 5.3 SANOFI-AVENTIS VIETNAM COMPANY
    • 5.3.1 Company Introduction
    • 5.3.2 Analysis of Human Vaccines Imports
  • 5.4 Importer 4
    • 5.4.1 Company Introduction
    • 5.4.2 Analysis of Human Vaccines Imports
  • 5.5 Importer 5
    • 5.5.1 Company Introduction
    • 5.5.2 Analysis of Human Vaccines Imports
  • 5.6 Importer 6
    • 5.6.1 Company Introduction
    • 5.6.2 Analysis of Human Vaccines Imports
  • 5.7 Importer 7
    • 5.7.1 Company Introduction
    • 5.7.2 Analysis of Human Vaccines Imports
  • 5.8 Importer 8
    • 5.8.1 Company Introduction
    • 5.8.2 Analysis of Human Vaccines Imports
  • 5.9 Importer 9
    • 5.9.1 Company Introduction
    • 5.9.2 Analysis of Human Vaccines Imports
  • 5.10 Importer 10
    • 5.10.1 Company Introduction
    • 5.10.2 Analysis of Human Vaccines Imports

6. Monthly Analysis of Human Vaccines Imports in Vietnam from 2021 to 2024

  • 6.1 Analysis of Monthly Import Value and Volume
  • 6.2 Forecast of Monthly Average Import Prices

7. Key Factors Affecting Human Vaccines Imports in Vietnam

  • 7.1 Policy
    • 7.1.1 Current Import Policies
    • 7.1.2 Trend Predictions for Import Policies
  • 7.2 Economic
    • 7.2.1 Market Prices
    • 7.2.2 Growth Trends of Human Vaccines Production Capacity in Vietnam
  • 7.3 Technology

8. Forecast for the Import of Human Vaccines in Vietnam, 2024-2033

Disclaimer

Service Guarantees

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦